Choice of antihypertensive treatment in subjects with pre-diabetes. is there a dream after the navigator

Current Vascular Pharmacology

Volumn 9, Issue 6, 2011, Pages 715-722

  Eleftheriadou, Ioanna ^a   Tsioufis, Costas ^a   Tsiachris, Dimitrios ^a   Tentolouris, Nicholas ^b   Stefanadis, Christodoulos ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Antihypertensive treatment; Cardiovascular disease; Hypertension; Insulin sensitivity; Pre diabetes; Renin angiotensin system

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIAL NITRIC OXIDE SYNTHASE; METOPROLOL; NEBIVOLOL; PLACEBO; TELMISARTAN; VASODILATOR AGENT;

ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE COURSE; GLUCOSE METABOLISM; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; DIURETICS; HUMANS; HYPERTENSION; PREDIABETIC STATE; RISK FACTORS;

EID: 80054084049     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016111797484099     Document Type: Article

References (64)

1. Nathan DM, Davidson MB, DeFronzo RA, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007; 30: 753-759.
2. Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, prediabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28: 88-136.
3. Segura J, Campo C, Ruilope LM, Rodicio JL. Do we need to target 'prediabetic' hypertensive patients? J Hypertens 2005; 23: 2119-2125.
4. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-1187.
5. Karagiannis A, Tziomalos K, Anagnostis P, et al. The Effect of Antihypertensive Agents on Insulin Sensitivity, Lipids and Haemostasis. Curr Vasc Pharmacol 2010; 8: 792-803
6. Arauz-Pacheco C, Parrott MA, Raskin P. Treatment of hypertension in adults with diabetes. Diabetes Care 2003; 26(Suppl 1): S80-S82.
7. Muscogiuri G, Chavez A, Gastaldelli A, et al. The Crosstalk Between Insulin and Renin-Angiotensin-Aldosterone Signaling Systems and its Effect on Glucose Metabolism and Diabetes Prevention. Curr Vasc Pharmacol 2008; 6: 301-312.
8. Leung PS. The physiology of a local renin-angiotensin system in the pancreas. J Physiol 2007; 580: 31-37.
9. Carlsson PO, Berne C, Jansson L. Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia 1998; 41: 127-133.
10. Tikellis C, Wookey PJ, Candido R, Andrikopoulos S, Thomas MC, Cooper ME. Improved islet morphology after blockade of the renin- angiotensin system in the ZDF rat. Diabetes 2004; 53: 989-997.
11. McFarlane SI, Kumar A, Sowers JR. Mechanisms by which angiotensin- converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol 2003; 91: 30H-37H.
12. Ingelfinger JR, Solomon CG. Angiotensin-converting-enzyme inhibitors for impaired glucose tolerance--is there still hope? N Engl J Med 2006; 355: 1608-1610.
13. Henriksen EJ, Jacob S. Angiotensin converting enzyme inhibitors and modulation of skeletal muscle insulin resistance. Diabetes Obes Metab 2003; 5: 214-222.
14. Kon V, Jabs K. Angiotensin in atherosclerosis. Curr Opin Nephrol Hypertens 2004; 13: 291-297.
15. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004; 109: 2054-2057.
16. Folli F, Saad MJ, Velloso L, et al. Crosstalk between insulin and angiotensin II signalling systems. Exp Clin Endocrinol Diabetes 1999; 107: 133-9.
17. Zandbergen AA, Lamberts SW, Janssen JA, Bootsma AH. Shortterm administration of an angiotensin-receptor antagonist in patients with impaired fasting glucose improves insulin sensitivity and increases free IGF-I. Eur J Endocrinol 2006; 155: 293-296.
18. Agarwal R. Hypertension, hypokalemia, and thiazide-induced diabetes: a 3-way connection. Hypertension 2008; 52: 1012-1013.
19. Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 2006; 48: 219-224.
20. Andersson OK, Gudbrandsson T, Jamerson K. Metabolic adverse effects of thiazide diuretics: the importance of normokalaemia. J Intern Med 1991; 735: 89-96.
21. Klauser R, Prager R, Gaube S, et al. Metabolic effects of isradipine vs. hydrochlorothiazide in diabetes mellitus. Hypertension 1991; 17: 15-21.
22. Eriksson JW, Jansson PA, Carlberg B, et al. Hydrochlorothiazide, but not Candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the mechanisms for the diabetes preventing effect of Candesartan (MEDICA) Study. Hypertension 2008; 52: 1030-1037.
23. Siegel D, Swislocki AL. Effects of antihypertensives on glucose metabolism. Metab Syndr Relat Disord 2007; 5: 211-219.
24. Kraus D, Jager J, Meier B, Fasshauer M, Klein J. Aldosterone inhibits uncoupling protein-1, induces insulin resistance, and stimulates proinflammatory adipokines in adipocytes. Horm Metab Res 2005; 37: 455-459.
25. Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens 2006; 24: 3-10.
26. Jacob S, Rett K, Henriksen EJ. Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents? Am J Hypertens 1998; 11: 1258-1265.
27. Jacob S, Rett K, Wicklmayr M, Agrawal B, Augustin HJ, Dietze GJ. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens 1996; 14: 489-494.
28. Torp-Pedersen C, Metra M, Charlesworth A, et al. Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). Heart 2007; 93: 968-973.
29. Pollare T, Lithell H, Selinus I, Berne C. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ 1989; 298: 1152-1157.
30. Wicklmayr M, Rett K, Dietze G, Mehnert H. Effects of betablocking agents on insulin secretion and glucose disposal. Horm Metab Res 1990; 22: 29-33.
31. Agabiti-Rosei E, Rizzoni D. Metabolic profile of nebivolol, a betaadrenoceptor antagonist with unique characteristics. Drugs 2007; 67: 1097-1107.
32. Hedner T, Samuelsson O, Lindholm L. Effects of antihypertensive therapy on glucose tolerance: focus on calcium antagonists. J Intern Med 1991; 735: 101-111.
33. Trost BN, Weidmann P. Effects of calcium antagonists on diabetic subjects: a review. J Hypertens 1987; (Suppl 5): S81-S104.
34. Murphy MB, Lewis PJ, Kohner E, Schumer B, Dollery CT. Glucose intolerance in hypertensive patients treated with diuretics; a fourteen-year follow-up. Lancet 1982; 2: 1293-1295.
35. Berglund G, Andersson O, Widgren B. Low-dose antihypertensive treatment with a thiazide diuretic is not diabetogenic. A 10-year controlled trial with bendroflumethiazide. Acta Med Scand 1986; 220: 419-424.
36. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensinconverting- enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-616.
37. Yusuf S, Gerstein H, Hoogwerf B, et al. Ramipril and the development of diabetes. JAMA 2001; 286: 1882-1885.
38. Mancia G, Brown M, Castaigne A, et al. Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and non-diabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension 2003; 41: 431-436.
39. Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and betablockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356: 359-365.
40. Lindholm LH, Ibsen H, Borch-Johnsen K, et al. Risk of new-onset diabetes in the Losartan Intervention for Endpoint reduction in hypertension study. J Hypertens 2002; 20: 1879-1886.
41. Vermes E, Ducharme A, Bourassa MG, Lessard M, White M, Tardif JC. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation 2003; 107: 1291-1296.
42. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs. a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805-2816.
43. Yusuf S, Ostergren JB, Gerstein HC, et al. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation 2005; 112: 48-53.
44. Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003; 21: 1563-1574.
45. Barzilay JI, Davis BR, Cutler JA, et al. Fasting glucose levels and incident diabetes mellitus in older non-diabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2006; 166: 2191-2201.
46. Whelton PK, Barzilay J, Cushman WC, et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005; 165: 1401-1409.
47. Black HR, Davis B, Barzilay J, et al. Metabolic and clinical outcomes in non-diabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care 2008; 31: 353-360.
48. Kjeldsen SE, McInnes GT, Mancia G, et al. Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: the VALUE trial. Blood Press 2008; 17: 170-177.
49. Gupta AK, Dahlof B, Dobson J, Sever PS, Wedel H, Poulter NR. Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial--Blood Pressure Lowering Arm and the relative influence of antihypertensive medication. Diabetes Care 2008; 31: 982-988.
50. Yusuf S, Diener HC, Sacco RL, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008; 359: 1225-1237.
51. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369: 201-207.
52. Liberopoulos EN, Tsouli S, Mikhailidis DP, Elisaf MS. Preventing type 2 diabetes in high risk patients: an overview of lifestyle and pharmacological measures. Curr Drug Targets 2006; 7: 211-228.
53. Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Lipidlowering agents and new onset diabetes mellitus. Expert Opin Pharmacother 2010; 11: 1965-70.
54. Bakris G, Molitch M, Hewkin A, et al. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006; 29: 2592-2597.
55. Bakris G, Molitch M, Zhou Q, et al. Reversal of diuretic-associated impaired glucose tolerance and new-onset diabetes: results of the STAR-LET study. J Cardiometab Syndr 2008; 3: 18-25.
56. Bosch J, Yusuf S, Gerstein HC, et al. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006; 355: 1551-1562.
57. Califf RM, Boolell M, Haffner SM, et al. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. Am Heart J 2008; 156: 623-632.
58. McMurray JJ, Holman RR, Haffner SM, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010; 362: 1477-1490.
59. Zidek W, Schrader J, Luders S, et al. First-line antihypertensive treatment in patients with pre-diabetes: rationale, design and baseline results of the ADaPT investigation. Cardiovasc Diabetol 2008; 7: 22.
60. Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004: 43: 963.
61. Almgren T, Wilhelmsen L, Samuelsson O, Himmelmann A, Rosengren A, Andersson O. Diabetes in treated hypertension is common and carries a high cardiovascular risk: results from a 28- year follow-up. J Hypertens 2007; 25: 1311-1317.
62. Tsiachris D, Tsioufis C, Thomopoulos C, et al. New-onset diabetes and cardiovascular events in essential hypertensives: a 6-year follow- up study. Int J Cardiol 2010 (in press).
63. Aksnes TA, Kjeldsen SE, Rostrup M, Omvik P, Hua TA, Julius S. Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial population. Hypertension 2007; 50: 467-473.
64. Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1575-1585.